Document:

Exhibit 4.4

 

THIS NOTE HAS NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"), OR UNDER THE SECURITIES LAWS OF ANY STATES. THESE SECURITIES ARE SUBJECT
TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE ACT AND THE APPLICABLE
STATE SECURITIES LAWS, PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM AND RECEIPT BY THE ISSUER OF AN OPINION OF COUNSEL IN FORM
AND SUBSTANCE SATISFACTORY TO THE ISSUER TO THE EFFECT THAT ANY PROPOSED TRANSFER OR RESALE IS IN COMPLIANCE WITH THE ACT AND ANY
APPLICABLE STATE SECURITIES LAWS.

 

PROPANC HEALTH GROUP CORPORATION

UNSECURED
JUNIOR SUBORDINATED PROMISSORY NOTE

DUE JUNE 1, 2017

 

	$20,000.00	December 1, 2016

 

		1.	Principal and Interest

 

FOR
VALUE RECEIVED, Propanc Health Group Corporation (the “Company”),
hereby absolutely and unconditionally promises to pay to GHS Investments LLC, a Nevada Limited Liability Company, or its registered
assigns (the “Lender”), the principal amount of Twenty Thousand Dollars ($20,000.00) on June 1, 2017 (the “Maturity
Date”). This Note shall bear simple interest at the rate of five percent (5%) per annum.         

 

The Lender, for itself
and its successors and assigns, acknowledges and agrees that this Note, and the payment of amounts due hereunder, are junior to
and subordinate in all respects to the existing debt of the Company pursuant to that certain 5% Original Issue Discount Senior
Secured Convertible Debenture with an original issue date of October 28, 2015 (the “2015 Debenture”), and the 5% Original
Issue Discount Senior Secured Convertible Debenture with an original issue date of September 13, 2016 (the “2016 Debenture”),
in each case issued by the Company to Delafield Investments Limited (“Delafield”), as amended, modified, supplemented,
restated, refinanced or replaced from time to time. Notwithstanding anything to the contrary herein, no payment pursuant to this
Note will occur until such time as the 2015 Debenture and 2016 Debenture have been fully repaid. Any delay in the payment hereunder
as a result of this subordination will not trigger any right to rescind, penalty or event of default hereunder.

 

		2.	Repayments and Prepayments; Security.

 

a.           Subject
to the second paragraph of Section 1, all principal and interest under this Note shall be due and payable on the Maturity
Date.

 

    	 	1	 

     

    

 

b.           Subject
to the second paragraph of Section 1, the Company may prepay this Note at any time. This Note may not be assigned by the
Lender, except by operation of law.

 

c.           This
Note is a general unsecured obligation of the Company.

 

		3.	Events of Default; Acceleration.

 

a.            The
principal amount of this Note is subject to prepayment in whole or in part upon the occurrence and during the continuance of any
of the following events (each, an “Event of Default”): the initiation of any bankruptcy, insolvency, moratorium, receivership
or reorganization by or against the Company, or a general assignment of assets by the Company for the benefit of creditors. Subject
to the second paragraph of Section 1, upon the occurrence of any Event of Default, the entire unpaid principal balance of this
Note and all of the unpaid interest accrued thereon shall be immediately due and payable. 

 

b.            No
remedy herein conferred upon the Lender is intended to be exclusive of any other remedy and each and every remedy shall be cumulative
and in addition to every other remedy hereunder, now or hereafter existing at law or in equity or otherwise. The Company accepts
and agrees that this Note is a full recourse note and that the Lender may exercise any and all remedies available to it under law.

 

		4.	Notices.

 

a.            All notices, reports
and other communications required or permitted hereunder shall be in writing and may be delivered in person, by telecopy with written
confirmation, overnight delivery service or U.S. mail, in which event it shall be mailed by first-class, certified or registered,
postage prepaid, addressed (i) if to a Lender, at such Lender’s address as the Lender shall have furnished the Company
in writing and (ii) if to the Company at such address as the Company shall have furnished the Lender in writing.

 

b.           Each
such notice, report or other communication shall for all purposes under this Note be treated as effective or having been given
when delivered if delivered personally or, if sent by mail, at the earlier of its receipt or 72 hours after the same has been deposited
in a regularly maintained receptacle for the deposit of the United States mail, addressed and mailed as aforesaid, or, if sent
by electronic communication with confirmation, upon the delivery of electronic communication.

 

		5.	Miscellaneous.

 

a.           
Neither this Note nor any provisions hereof may be changed, waived, discharged or terminated orally, but only by a signed statement
in writing executed by both parties hereto.

 

    	 	2	 

     

    

 

b.           No
failure or delay by the Lender to exercise any right hereunder shall operate as a waiver thereof, nor shall any single or partial
exercise of any right, power or privilege preclude any other right, power or privilege. The provisions of this Note are severable
and if any one provision hereof shall be held invalid or unenforceable in whole or in part in any jurisdiction, such invalidity
or unenforceability shall affect only such provision in such jurisdiction. This Note expresses the entire understanding of the
parties with respect to the transactions contemplated hereby. The Company hereby waives presentment, demand, protest and notice
of every kind.

 

c.           This
Note shall for all purposes be governed by, and construed in accordance with the laws of the State of New York (without reference
to conflict of laws).

 

d.           This
Note shall be binding upon the Company's successors and assigns, and shall inure to the benefit of the Lender's successors and
permitted assigns.

 

    	 	3	 

     

    

 

IN WITNESS WHEREOF, the Company has caused this Note to be executed
by its duly authorized officer to take effect as of the date first hereinabove written.

 

	 	PROPANC HEALTH GROUP CORPORATION
	 	 	 
	 	By:	 
	 	 	 
	 	Title:	 

 

[Note between Propanc and GHS Investments]Exhibit 10.1

 

[PROPANC HEALTH GROUP CORPORATION LETTERHEAD]

 

December 2, 2016

 

Delafield Investments Limited

c/o Joshua Sason, Director

Magna

40 Wall Street, 58th Floor

New York, New York 10005

 

RE: Revised financing terms and documents

 

Gentlemen:

 

Reference is hereby made
to the Two Year Common Stock Purchase Warrant (the “Two Year Warrant”), to purchase up to 40,000,000 shares of common
stock, par value $0.001 per share (the “Common Stock”), of Propanc Health Group Corporation (the “Company”)
at an exercise price of $0.10 per share, and the Five Month Common Stock Purchase Warrant (the “Five Month Warrant”),
to purchase in five tranches, at exercise prices between $0.012 and $0.020 per share, up to 200,000,000 shares of Common Stock.
Collectively, the Two Year Warrant and the Five Month Warrant are referred to herein as the “Warrants”). The Warrants
were issued to Delafield Investments Limited (“Delafield”) on August 3, 2016. On August 18, 2016, Delafield notified
us of its exercise of 12,500,000 shares of Common Stock under the first tranche of the Five Month Warrant at a purchase price of
$0.012 per share or $150,000 in the aggregate.

 

By the signature of your
authorized representative below, and for good and valuable consideration the value and receipt of which are hereby acknowledged,
Delafield acknowledges and agrees that, notwithstanding anything in the Warrants to the contrary, each of the Two Year Warrant
and the Five Month Warrant are hereby cancelled and shall hereafter be null, void and of no further force and effect. Delafield
agrees that the 12,500,000 shares of Common Stock held by Delafield as restricted securities are to be redeemed by the Company
upon the issuance and in exchange for an 8% convertible redeemable promissory note in the principal amount of $150,000.00 with
a maturity date two years from the issuance date. In addition, Delafield releases the Company from any and all obligations to register
the shares underlying the Warrants and authorizes the Company to withdraw its Registration Statement on Form S-1, together with
all exhibits thereto (File No. 333-213216) filed with the Securities and Exchange Commission on August 19, 2016 with respect to
such shares. Further, Delafield releases the Company from any and all obligations to reserve from its authorized and unissued shares
of Common Stock, 240,000,000 shares in connection with or underlying the Warrants and authorizes the Company to advise its transfer
agent accordingly. The Company will continue to reserve 433,149,094 shares of Common Stock in connection with the 2015 Debenture
and the Additional Issuance Debenture, each as defined below.

 

     

     

    

 

Delafield, on behalf of
itself and its affiliates, successors and assigns, consents to and agrees that notwithstanding anything to the contrary, including
but not limited to any provision or term of the Warrants, the Securities Purchase Agreement by and between the Company and Delafield
dated as of October 28, 2015 as amended by an addendum dated March 11, 2016, a letter agreement dated July 1, 2016 and a letter
agreement dated August 3, 2016 (collectively, the “Securities Purchase Agreement”), the Convertible Debenture in the
original principal amount of $4,400,000 issued by the Company to Delafield in connection with the Securities Purchase Agreement
(the “2015 Debenture”), the Security Agreement by and between the Company and Delafield dated as of October 28, 2015,
the Additional Issuance Agreement between the Company and Delafield dated as of September 13, 2016, and the 5% Original Issue Discount
Senior Secured Convertible Debenture of the Company issued to Delafield in the principal amount of $165,000 (the “Additional
Issuance Debenture”), the Company, at any time and from time to time prior to the repayment of the 2015 Debenture and the
Additional Issuance Debenture, may agree to issue and may issue shares of Common Stock upon conversion of a convertible security.
In addition, Delafield specifically waives compliance by the Company with the obligations imposed by Sections 7(d) and 7(e) of
each of the 2015 Debenture and the Additional Issuance Debenture with respect to any future issuances or repayments or offers thereof
of shares of Common Stock or Common Stock Equivalents or Indebtedness (as defined in the 2015 Debenture and Additional Issuance
Debenture) in connection with any issuance of shares of Common Stock upon conversion of a convertible security. The consent and
waivers contained herein are intended to be generally construed and applied. In no event will any actions by the Company pursuant
hereto be considered an event of default under any of the transaction documents between the Company and Delafield in connection
with the consent provided herein and the obligations waived pursuant hereto.

 

In consideration of the
foregoing, the Company agrees to issue Delafield a two year common stock purchase warrant to purchase 26,000,000 shares of Common
Stock at an exercise price of $0.05 per share.

 

Delafield, for itself and
its affiliates, successors and assigns, releases any and all rights or claims that it may have against the Company, its directors,
officers, subsidiaries, affiliates, representatives, agents and successors arising in any way under the Two Year Warrant or the
Five Month Warrant, respectively, shares exercised under the Warrants, or the right to purchase capital stock of the Company thereunder.

 

This letter may be executed
and delivered via facsimile or other electronic means with the same force and effect as if an original were executed and may be
signed in any number of counterparts, each of which shall be an original, with the same effect as if the signatures hereto were
upon the same instrument.

 

[Signature page follows.]

 

     

     

    

 

Please indicate that you
acknowledge and agree to the foregoing by signing this letter in the space below and returning it as soon as possible to my attention
via email at j.nathanielsz@propanc.com, with a copy to amcclean@hselaw.com.

 

	 	Sincerely,
	 	 
	 	Propanc Health Group Corporation
	 	 	 
	 	By:	 
	 	Name: James Nathanielsz
	 	Title: Chief Executive Officer

 

Accepted and Agreed

As of this ___ day of December 2016.

 

	Name of Holder:	Delafield Investments Limited	 
	Signature of Authorized Signatory of Holder:	 	 
	Name of Authorized Signatory:	 	 
	Title of Authorized Signatory:	 	 
	 	 	 
	Name of Holder:	Delafield Investments Limited	 
	Signature of Authorized Signatory of Holder:	 	 
	Name of Authorized Signatory:	 	 
	Title of Authorized Signatory:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00265-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00265-of-00352.parquet"}]]